Company intelligence / Profile preview

Phoenix Pharmacologics Inc.

Lexington, Kentucky, United States

Ownership: Private
Development stage: Other

Overview

Phoenix Pharmacologics was an emerging biopharmaceutical company developing pegylated enzyme therapeutics and small molecule inhibitors primarily targeting cancer and metabolic diseases. Its lead programs included ADI‑PEG20 in Phase II trials for liver cancer and melanoma, and Uricase‑PEG20 post–Phase I for gout-related conditions. In March 2006, Polaris Pharmaceuticals acquired the intellectual property portfolio of Phoenix Pharmacologics, including these assets as well as early-stage agents like TNF‑PEG20, Histidase‑PEG20, and casein kinase inhibitors.

Therapeutic areas: Metabolic DisordersOncologyRheumatology
Modalities: Enzyme therapeutics (pegylated enzymes)Small molecule inhibitors
Industry: Biotech

Beyond the preview

Go deeper on Phoenix Pharmacologics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoenix Pharmacologics Inc..